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EXECUTIVE SUMMARY
While there has been remarkable global progress in the prevention of mother-to-child HIV
transmission (PMTCT), efforts to scale up antiretroviral therapy (ART) and achieve the Joint United
Nations Programme on HIV/AIDS (UNAIDS) “90–90–90” targets (90% diagnosed, 90% of those
infected on ART, 90% on ART viral suppressed) have been less robust in children than in adults
living with HIV. These discrepancies reflect substantial gaps in essential services and numerous
missed opportunities to engage children in care and provide effective treatment. Although not
new, family-centered care models that provide HIV services comprehensively to families as a
unit, rather than providing separate services to children and adults, have the potential to address
family needs and break down social, physical, and emotional barriers to accessing care. The
family-centered care study (FAM-CARE) aims to contribute to our understanding of the role of
family-centered care models (FCCM) in improving pediatric HIV outcomes in a sub-Saharan
African setting.

Methodology
The FCCM program is a model where a child or adolescent (0–<19 years old) living with HIV
is provided HIV care and treatment services with at least one family member involved in the
support for the child. Family members include children and adults, HIV-negative and HIV-positive.
For family members who have unknown HIV status, HIV counseling and testing and follow up
services are provided. Participants attend clinic visits together as a family unit to receive HIV care,
including laboratory and pharmacy services. Participants see the same provider at each visit,
medications for family members could be collected by one family member, and a comprehensive
filing system allowed all clinical records for each family to be stored in one folder. Clinic visits are
scheduled for a minimum of four visits per year; all medical records are to be pulled for all family
members ahead of the visit and FCCM participants prioritized in receiving services at the facility.
The FAM-CARE study enrolled a prospective cohort of children living with HIV (age <15 years)
and their caregivers (HIV-positive or HIV-negative) and other family members living with HIV to
evaluate the effects of a FCCM. Four facility clusters (two hospitals and two health facilities, and
their filter clinics) in the Hhohho region of Eswatini were randomized to either implement the
FCCM intervention, where all family members living with HIV are seen together as a unit and
receive their care together, or to the control standard of care group, where adults and children
are seen in separate clinics. The cohort of 379 children living with HIV was followed in both
arms for a minimum of 12 months after enrollment. The primary objective was to evaluate the
effect of the FCCM program on the rates of viral suppression and retention in care, comparing
children enrolled in FCCM versus control sites. The study also evaluated factors associated with
viral suppression and retention. Caregiver interviews and medical chart abstraction were used
to collect data on demographic characteristics, HIV and ART history, interim HIV history, viral
load, CD4 count, medical visit attendance, and drug pick-ups for children living with HIV and
any caregivers or family members living with HIV. For children, viral load was obtained as part
of the study at enrollment, 6, and 12 months (and 18 months for those followed through that
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time), with laboratory assays conducted at a central laboratory. Qualitative in-depth interviews
with caregivers and health workers at the intervention sites were used to assess feasibility and
acceptability of the FCCM model.

KEY FINDINGS
Quantitative findings
A cohort of 379 children living with HIV and their caregivers from 363 unique families, including
363 caregivers (97% living with HIV themselves) and 28 other family members living with HIV
(children, adolescents, and adults), were enrolled and followed for a minimum of 12 months;
87 percent had follow-up through 12 months and 57 percent through 18 months. Other family
members included children, adolescents, and adults living with HIV, living in the same household
as the child living with HIV enrolled in the FAM-CARE study.

Treatment regimen at enrollment
At enrollment, 43 percent of children were receiving nevirapine-based ART regimens. These
nevirapine-based regimens are considered suboptimal and were associated with lower levels
of viral suppression. These findings directed attention to the critical need to review pediatric
treatment regimens and optimize ART regimens for all children as they grow and as more potent
and less toxic regimens become available. These findings were published in 2019 in the Pediatric
Infectious Diseases Journal.

Viral suppression and undetectable viremia
Viral suppression (HIV RNA <1,000 copies/mL) improved in both study arms from 78 percent
at enrollment to 90 percent at 12 months and 87 percent for those followed to 18 months.
Children with undetectable viral load (HIV RNA <400 copies/mL) improved from 74 percent at
enrollment to 87 percent at 12 months and 84 percent for those followed to 18 months. Overall,
among children who had viral suppression at enrollment, 97 percent remained suppressed at
12 months follow up; 62 percent of children who were unsuppressed at enrollment achieved
viral suppression at 12 months follow up. There were no statistically significant differences in
the intervention versus control groups in viral suppression or undetectable viral load at 12 or 18
months follow-up.

Factors associated with viral suppression and undetectable viremia
In unadjusted bivariate analyses among all children at 12 months after enrollment, several
factors were associated with viral suppression (HIV RNA <1,000 copies/mL). Children who were
not aware of their HIV status tended to be less likely than children who were aware of their HIV
status to be virally suppressed (OR:0.46; 95% CI:0.20, 1.08, p=0.068). Compared to children with
caregivers under age 25 years, children with older caregivers aged 30–40 years (OR: 5.53; 95%
CI: 1.80, 17.00) and aged >40 years (OR: 3.93; 95% CI:1.30, 11.85) were significantly more likely
to be suppressed. The odds of suppression among children with HIV-negative caregivers were
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significantly lower than the odds of suppression among children with HIV-positive caregivers (OR:
0.15; 95% CI: 0.05, 0.49). At study entry, children on nevirapine (NVP)-based ART had significantly
lower levels of viral suppression (73%) than those on efavirenz (EFV) (87%) or lopinavir-ritonavir
(LPV/r)-based (79%) ART (p=0.042). At 12 months, while rates of viral suppression remained
lowest in those on NVP-based ART (87%) compared to EFV-based (94%) and LPV/r-based (91%)
ART, this was not statistically significant (p=0.31). Study intervention versus control group was
not significantly associated with viral suppression at 12 (p=0.48) or 18 months (p=0.08) after
enrollment.
In unadjusted bivariate analyses among all children at 12 months after enrollment, similar factors
were associated with undetectable viremia (HIV RNA <400 copies/mL). The odds of undetectable
viremia tended to be lower among children who did not know their HIV status compared to
children who knew their HIV status (OR: 0.55; 95% CI: 0.26, 1.14, p=0.10). Children in the care
of caregivers aged 30–40 years (OR: 5.24; 95% CI: 1,83, 15.04) and aged >40 years (OR:3.15;
95% CI: 1.14, 8.68) were significantly more likely to have undetectable viremia than children
with younger aged caregivers (<25 years). Children in the care of HIV-negative caregivers versus
caregivers living with HIV were less likely to have undetectable viremia (OR:0.15; 95% CI: 0.05,
0.46). Although rates of undetectable viremia at 12 months after enrollment were lowest in those
on NVP-based ART (84%) compared to EFV-based (90%) and LPV/r-based (89%) ART, this was
not statistically significant (p=0.38). Study intervention versus control group was not significantly
associated with undetectable viremia at 12 (p=0.63) or 18 months (p=0.38) after enrollment.
There was a non-significant trend toward higher odds of viral suppression and undetectable
viremia among older versus younger children. Overall, 94 percent of children aged 10–14 years
had viral suppression at 12 months follow-up compared with 90 percent of children aged 5–9
years and 85 percent of children aged <5 years. Similarly, undetectable viral load was observed in
91 percent of children 10-14 years, 87 percent of those aged 5–9 years, and 81 percent of those
aged <5 years. There was not a significant difference in the levels of suppression or detectability
by intervention versus control groups when stratified by age.

Retention, adherence, treatment interruption, and HIV disclosure
There were no significant differences between intervention and control groups in retention in
care, interruption of ART, reported adherence, or disclosure at 12 months (Table 5). At 12 months
follow-up, 93 percent of children expected to be seen at the 12-month visit had a documented
clinic visit, with no significant difference between groups (91% intervention, 94% control,
p=0.53). At the 12-month visit, ART interruption was reported by 16 percent in the intervention
and 15 percent in the control groups (p=0.82); good adherence was reported by 84 percent in
the intervention and 87 percent of the control groups (p=0.32); and last two drug pick-ups were
reported to be on time for 88 percent of intervention and 92 percent of control group children
(p=0.18). The proportion of children who did not know their HIV status at enrollment but learned
of their HIV status during the study was low and not statistically different between groups (6%
intervention and 5% control, p=0.69). In the more limited sample of 216 children with 18-month
follow-up, 12 percent reported ART interruption, 93 percent reported good ART adherence, and
87% percent reported the last two drug pick-ups were on time, with no significant differences
between groups.

Piloting and evaluating family-centered care in Eswatini ■ 3

Qualitative findings
Benefits of FCCM
Caregivers liked the FCCM model because they felt it encouraged family members to disclose
their HIV status to other family members and support each other in taking antiretroviral (ARV)
drug regimens. Caregivers reported that they thought FCCM encouraged men to take a proactive
support role for both women and children in HIV care and treatment, and reduced HIV-related
stigma within the family. Caregivers viewed the counseling as better in the FCCM program than it
was in the standard of care.
Health workers said FCCM program allowed them to track family histories, identify family
challenges to HIV care and treatment, and identify long lasting solutions to problems. Overall,
health workers perceived improved ART adherence, retention, and health status of children in the
FCCM program.

Challenges in FCCM
Caregivers felt they had to incur additional costs for clinic visits for multiple family members, as
the FCCM program required the family to visit the clinic together. There were schedule conflicts
with school-aged children attending school and conflicts for older children who also attended
weekend teen-support groups, as FCCM required additional family visits.
Within some facilities, health workers said that not all families attended clinic visits together
as a family unit. Some families rotated family members to pick up ARV drug refills for the whole
family. Health workers also had challenges with managing a large group of family members at the
same time and noted staff shortages. Both caregivers and health workers mentioned difficulty in
discussing sensitive health information in the presence of other family members.

CONCLUSION AND RECOMMENDATIONS
High levels of viral suppression and ART adherence (90% and 85% overall, respectively) as well
as retention were observed in both arms of the FAM-CARE study, which made it difficult to detect
differences between children in control and intervention arms. Younger caregivers were less likely
to have a child with viral suppression, and viral suppression was lower among children aged <5
years compared to older children.
The standard of care in Eswatini during the study period included viral load monitoring every
12 months for stable children less than 10 years old and every 6 months for children aged 10
to 19 years, and availability of teen support groups. Both intervention and control sites were to
receive routine viral load testing every six months (although this was not always followed in the
control sites) and the availability of teen support groups. In the control sites, it is possible that the
additional attention of being enrolled in a study, with the caregiver interviewed at each study visit,
resulted in improved viral suppression in this group, which limited the ability to detect a difference
between control and intervention group participants.
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The FCCM program was well-liked by both caregivers and health care workers overall. Both
caregivers and health workers viewed FCCM as encouraging HIV disclosure among family
members and supporting each other in ART adherence, although analysis of FAM-CARE study
data did not find differences in new HIV status disclosures to children or in ART adherence
between study groups. Challenges discussed by both caregivers and health workers included
clinic visit scheduling conflicts with school and teen support groups, making it difficult to
implement FCCM as planned, as well as difficulties in discussing sensitive health information in
the presence of other family members.
These results reflect the significant challenges for families with school-aged children in attending
clinic visits together as a family as FCCM intended. For older children, teen support groups may
be sufficient for ensuring positive outcomes in viral suppression and undetectable viremia. A
higher proportion of older children achieved viral suppression and undetectable viremia (94% and
91%, respectively, for those aged 10–14 years) in both arms at 12 months after enrollment than
the younger children (85% and 82% respectively, for those aged <5 years).
Factors associated with viral suppression highlight important areas for enhancement in pediatric
HIV care. Additional support (e.g., for keeping appointments, retention, understanding the need to
take medication as prescribed, adherece) for adolescent or young adult caregivers, HIV-negative
caregivers, caregivers of children under age 5 years, and for all caregivers in disclosing the child’s
HIV status could improve pediatric HIV outcomes.
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INTRODUCTION
Over the past two decades there has been much progress in prevention of mother-to-child HIV
transmission in efforts to scale up antiretroviral therapy (ART) and achieve the Joint United
Nations Programme on HIV/AIDS (UNAIDS) “90–90–90” targets (90% diagnosis, 90% of those
infected-on ART, 90% on ART with viral suppression). Achievement toward these goals has been
less robust for children compared with adults (WHO 2014; UNAIDS 2014). These discrepancies
reflect substantial gaps in essential services and numerous missed opportunities to engage
children in care and provide effective ART.
With the 2016 WHO recommendations for universal treatment of all individuals living with HIV
regardless of clinical or immune status, parents and children living with HIV will require ART
(WHO 2016). The family forms the basic source of care and support for children in sub-Saharan
Africa, and children’s health and well-being are dependent on the physical, emotional, and
social health of their parents and caregivers; a major aim of ART is to keep the family unit alive
and well, benefitting caregivers and parents and also improving the well-being of their children
(Leeper et al. 2010). Most HIV services are delivered with a focus on individual care, with little
or less attention to their family or social context. Provision of ART has generally been separated
for adults and children because of different areas of expertise and because prior treatment
guidelines were dependent on CD4 and WHO clinical stage for ART eligibility, and children and
their parents may have qualified for treatment months or years apart. However, comprehensive
pediatric HIV prevention, treatment, and support will likely not be achieved if the child is taken
out of the context of the family. Family-centered care models (FCCM) have emerged as an
approach to comprehensively care for the needs of all HIV-positive family members, particularly
the mother and child (Ritcher et al. 2010). Approaches that engage the family as a whole may
offer advantages in improving retention in care and adherence with ART over the long run, and
breaking barriers related to male partner involvement and disclosure processes (Rochat et al.
2011; Beatancourt et al. 2010).
While these models are not new, there are limited data to provide insights on the role of
FCCM on pediatric and adult HIV outcomes. A 7-year retrospective analysis of data following
implementation of an integrated family-focused approach to pediatric HIV care in 10 health
facilities and 10 community clinics in Uganda reported a 50-fold increase in family units
registered in health care (from 70 to 3,653), a 43-fold increase in children actively enrolled in
care (from 86 to 3,726) and a 23-fold increase in children receiving ART (from 86 to 2,015)
(Luyirika et al. 2013). In a study that examined the association between co-enrollment of family
members living with HIV into care and outcomes of women initiating ART for PMTCT in 12 HIV care
and treatment programs in eight sub-Saharan African countries, the risk of loss to follow-up was
significantly greater among women living with HIV who did not have a family member living with
HIV co-enrolled in care compared to those with a family member enrolled (19% vs 3–8% after 36
months on ART, respectively) (Myer et al. 2014). These limited data suggest that a family-focused
care approach may lead to improved retention, ART adherence, and viral suppression for both
children and adults. However, implementation of such a program has also been found to have
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challenges, including issues of disclosure to partners and difficulties in engaging male partners
(Towne-Gold et al. 2009; Hosegood et al. 2010).
Additionally, achieving the third “90” (90% viral suppression) is particularly challenging in children
as most programs do not include pediatric viral load monitoring as part of routine care. The
use of 2010/2013 WHO immunologic criteria to define treatment failure results in significant
misclassification: in a study in Western Kenya, 6 percent (2 of 34) of children classified as
treatment failure actually had undetectable viral load, and 65 percent (45 of 69) of children
thought to have treatment success had detectable viral load, supporting WHO recommendations
for routine viral load monitoring (Dufort et al. 2016). The potential use of viral load monitoring as
a tool to promote adherence has had some evaluation among adults, but not among children. A
meta-analysis of eight studies in eight countries found a trend for re-suppression following viral
load testing with targeted adherence support for adults living with HIV found to have detectable
viremia (Bonner et al. 2013). Studies are critically needed to determine how to optimally
implement and use virologic testing among children living with HIV (Roberts et al. 2016).
In a recent large cross-sectional survey in Malawi and a 2013 systematic review of viral
suppression in adults living with HIV on ART, viral suppression to HIV RNA <1,000 copies/mL
ranged from 62 to 71 percent (intention-to-treat analysis) (McMahon et al. 2013; Maman et al.
2016). Data on virologic outcomes for children on ART in sub-Saharan Africa are more limited. In
a cross-sectional survey of viral suppression (HIV RNA <80 copies/mL) among children on firstline ART for >6 months in 10 nurse-led clinics in Lesotho, viral suppression was found in only
72 percent of 191 children; no predictors for viral outcome were identified (Puga et al. 2016).
Similarly, in a study of 742 children living with HIV initiating first-line ART in South Africa between
2008 and 2011, only 62 percent achieved a viral load <50 copies/mL six months after ART
initiation (Pillay et al. 2015). In a descriptive study using data from a pilot program in 2012–2013
of routine viral load monitoring in 12,063 individuals living with HIV (including 580 children <10
years and 588 adolescents 10–19 years) in Shiselweni, Eswatini, 16 percent were found to have
detectable viral load (HIV RNA ≥100 copies/mL); children had a 2.6-fold and adolescents a 3.2fold increased odds of having a detectable viral load (29% of children <10 years and 35% of
adolescents 10–19 years had detectable viremia) and were less likely to re-suppress at re-testing
after adherence counseling (Jobanputra et al. 2015). Thus, the available pediatric data suggest
viral suppression below the level of assay quantification (HIV RNA <50–400 copies/mL) is
observed in 62 to 78 percent of children after >6–24 months of ART. In a pooled analysis of data
from 5,485 children living with HIV who initiated ART at seven South African treatment programs
with viral load monitoring, the probability of having a single viral load measurement >1,000
copies/mL was 17 percent at one year (95% CI 15.8–18.1) and 32 percent (95% CI 30.2–34.1)
at 3 years after starting ART; the frequency of ART failure (two viral load >1,000 copies/mL) was
19 percent by 36 months (Davies et al. 2011). There are many factors that contribute to poor
overall virologic response to ART and problems with retention and ART adherence in children,
many of which stem from the fact that children are dependent upon adults for administration of
their medications and attendance at clinic appointments. A family-focused program of care may
serve to improve both pediatric retention in care and viral suppression.
In 2017, EGPAF-Eswatini initiated a pilot family-centered service delivery program in selected
health facilities in the Hhohho region to provide more efficient and effective services to promote
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better ART initiation and retention in care for adults and children. The roll-out of these services
provided a platform for introducing and evaluating routine HIV viral load testing and monitoring in
children. Two of four health care clinic clusters in the region were randomized to provide the new
FCCM, allowing a comparison of pediatric retention and viral load suppression between FCCM
program and control facilities in which care for adults and children are provided separately. Data
for the family care (FAM-CARE) study were collected during September 2017 and July 2019.
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METHODOLOGY
OBJECTIVES
The overall aim of this study was to demonstrate whether a family-centered care approach to HIV
care through FCCM improved rates of viral suppression and retention of children living with HIV in
care. The specific objectives of the FAM-CARE study were:

Primary objectives
1. Evaluate the effect of the FCCM program of HIV care on the proportion of children living with
HIV on ART with viral suppression (defined as HIV RNA copies/mL below the level of assay
detection) 18 months after enrollment.
2. Evaluate the effect of a FAM-CARE program of HIV care on the proportion of children living
with HIV on ART with HIV RNA ≥1,000 copies/mL 18 months after enrollment into the study.

Secondary objectives
1. Evaluate the effect of a FAM-CARE program of HIV care on the proportion of children with viral
suppression (undetectable HIV RNA levels) and with HIV RNA ≥1,000 copies/mL at 6 and 12
months after enrollment into the study.
2. Determine the individual and family factors associated with viral suppression and
undetectable viremia in children 12 months after enrollment in FCCM and control facilities.
3. Evaluate the effect of a FAM-CARE program of HIV care on loss to follow-up (not seen in
clinical care >3 months) and ART initiation in HIV-positive children not on ART at study entry.
4. Evaluate the acceptability of the FCCM program to caregivers and health care providers.

STUDY DESIGN
The FAM-CARE study was a two arm, prospective cohort study of HIV-positive children from
selected facility sites implementing the FCCM program and control sites using the standard of
care (separate adult and pediatric HIV care clinics) to assess the effects of the FCCM program
on retention and viral suppression in HIV-positive children on ART. Program health care facility
clusters were randomized to initiate the pilot FCCM program (two health care facility clusters) or
continue to provide the current standard of HIV care with separate pediatric and adult HIV clinics
(two health care facility clusters). The FAM-CARE study evaluated the effect of the program on
pediatric viral suppression and retention in care using both quantitative and qualitative methods.
Quantitative data collection included interviews conducted with caregivers to gather demographic,
medical history, family history, HIV, and treatment history for caregivers, children, and other family
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members; medical chart abstraction to gather information on visit attendance, HIV treatment,
pharmacy pick-up, and CD4 and viral load history if on ART for caregivers, children, and other
family members; and collection of dried blood spot (DBS) specimens from children to test for viral
load every six months. Data collection was conducted at enrollment and at every three months
for children and caregivers, and every 6 months for other family members, for a minimum of 12
months after enrolment. Qualitative one-on-one in-depth interviews (IDIs) were conducted with
randomly selected caregivers and with purposively selected health workers (HWs) at the FCCM
sites to assess feasibility and acceptability of the FCCM program.

Study setting and study population
The FAM-CARE study sites were selected from PEPFAR-supported health facilities in Hhohho
region, which consist of four clinic clusters consisting of a “parent” hospital or health center
(Mbabane Government Hospital, Pigg’s Peak Government Hospital, Emkhuzweni Health Centre,
and Dvokolwako Health Centre clusters) and the local filter clinics that feed into the primary
“parent” care center. For the FAM-CARE study, the four clusters and the accompanying largest
filter clinic for each cluster were randomized to initiate the FCCM program (Emkhuzweni and
Pigg’s Peak clusters and their respective filter clinics Mangweni and Horo clinics) or to remain
standard of care (Dvokolwako and Mbabane clusters and their respective filter clinics Balekane
Nazarene and Lobamba clinics). Figure 1 shows the schema of study design for the evaluation of
FCCM program (Appendix 1).
For the quantitative component, all children living with HIV under the age of 15 years receiving
care at a study facility were eligible for enrollment in the prospective cohort regardless of
treatment status if there was at least one other HIV-positive family member residing in the
household receiving services at that facility. Children living with HIV were excluded from the study
if they were attending care at a study facility only temporarily, they had no other HIV-positive
family members in the household receiving services at the study facility, or the child or caregiver
had a significant medical condition that would preclude active study participation. For the
qualitative component, caregivers were eligible for IDIs if they were enrolled in the FCCM program
at least 12 months prior to data collection and enrolled as a FAM-CARE study participant; HWs
were eligible for IDI if they provided care in the FCCM site for at least 6 months prior to data
collection.

Sample size
The sample size was powered to detect a difference in viral suppression (HIV RNA ≥1,000 copies/
mL) in children receiving ART in the FCCM sites to those receiving ART in control sites, with 80
percent power at 5 percent significance levels to detect at least a 10 percent increase in viral
suppression with FCCM, assuming a suppression rate of 80 percent in the control sites, or a 15
percent increase in suppression if the control suppression rate was no more than 75 percent.
Assuming 10 percent loss-to-follow-up, this required a sample of 444 HIV-positive children from
unique families (222 from intervention sites and 222 from control sites). The study originally
planned 18-month follow-up, but due to slower than expected enrollment, participants were
followed up to 12 months, with exploratory analyses used for those children who had been
followed up for 18 months to see if there were any differences in primary endpoints.
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DESCRIPTION OF INTERVENTION
The FCCM is a differentiated service delivery (DSD) model aimed at providing more efficient
and effective HIV services to promote better ART initiation and retention in families. At sites
randomized to implement FCCM, HIV-positive children were provided HIV services along with at
least one other family member (HIV-positive or HIV-negative) involved in the support of the child.
A family member was defined as someone related to the child either by blood or adoption, or
someone residing in the same household who was responsible for the child. Family members had
to be willing to disclose their HIV status to other family members within FCCM, attend clinic visits
with the child, and support the child during clinic visits and at home. Family members living with
HIV were invited to receive HIV care and treatment services at the same facility with the child,
and HIV-negative family members received non-communicable disease health care services.
All family members living with HIV were to be seen together in the facility and receive their care
together as a family unit, with chronic care files kept in one family folder. ART medications were
to be prepared for the family in advance of their visit and families were to be prioritized to be
seen (or seen on special clinic “family days”) to decrease waiting time. If all family members were
stable, one family member could pick up medications for the entire family. Families in FCCM were
seen at least once every quarter for family units with stable children as defined in the Eswatini
Integrated HIV Management Guidelines 2018 for children. Families not meeting these criteria
were seen monthly. For families with school-aged children, clinic visits were attempted to be
scheduled around school holidays. Staff were trained in FCCM standard operating procedures
(SOPs), which defined staff purpose, roles and responsibilities, and resources (Appendix 4 FCCM
SOP and Appendix 5 Components of the FCCM Service Package).

DATA COLLECTION METHODS
All data collectors were trained by EGPAF research staff. A five-day training was held for study
nurses who were responsible for collecting data in interviews and chart reviews. Qualitative
interviewers were trained in a separate five-day training that included qualitative data collection
methods and the qualitative data collection tools.
Following informed consent of the caregiver (and assent of children >12–14 years), data were
collected through caregiver interviews and abstraction of facility, laboratory, and patient records
using specific data collection forms. At enrollment, study nurses interviewed caregivers to collect
demographic, medical, and HIV-related information about the caregiver, the child, and household
members. Clinical laboratory data for caregivers, children, and other HIV-positive family members
were abstracted from clinic medical records. Study nurses collected DBS specimens from children
for viral load testing. Study follow-up visits were every three months for children and caregivers
and were scheduled to coincide with routine clinic visits to the extent possible. At each study visit,
study nurses obtained interim clinical history (e.g., medical/HIV history and CD4 count and, for
children on treatment, ART history, current regimen, and adherence) through caregiver interview
and medical chart abstraction. Data on clinic visit attendance and pharmacy drug pick-ups for
children receiving ART were obtained by chart abstraction. DBS specimens were drawn from HIVpositive children on ART for study viral load testing every six months. Data collection activities are
presented in Appendix 2.
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For the qualitative component, semi-structured one-on-one IDIs were conducted with caregivers
and HWs to assess feasibility and acceptability of the FCCM. All interviews were conducted in a
private room at the health facilities in the preferred language of participants, SiSwati. Interviews
took place during October to December 2018 in the four health facilities implementing the
pilot FCCM program (Appendix 3); one to four caregiver interviews were conducted at each site.
Eligible caregivers were selected from a list of caregivers enrolled in both the FCCM program
and the FAM-CARE study using a computer-aided simple random method. The FAM-CARE
study nurse contacted the selected caregiver to return on a scheduled day for the interview
and communicated with research assistants when the caregiver was scheduled for the
interview. Caregivers returning to the facility for the purpose of the interview received transport
reimbursement. Topics covered during the interviews included experiences engaging in the FCCM
program, views on the advantages and disadvantages of FCCM, and perceptions of differences
in the provision of care through FCCM compared to the standard of care. For HW interviews, FAMCARE study nurses worked with the site nurse-in-charge to identify eligible HWs (providers of care
in the FCCM program >6 months). If there were more HWs eligible than the range of IDIs selected
for the facility, each HW was assigned a number and selected at random by lottery. The FAM-CARE
study nurse contacted the selected HW and asked them to meet with the research assistant on
a scheduled day for the interview. Interviews covered views on advantages and disadvantages of
FCCM and barriers and facilitators in implementing the FCCM program.

ETHICAL REVIEW
The FAM-CARE study was reviewed and approved by Population Council Institutional Review Board
(IRB) and the National Health Research Review Board in Eswatini.

DATA ANALYSIS
Demographic characteristics at enrollment were summarized using means (standard deviations)
for continuous variables and proportions for categorical variables, stratified by FCCM intervention
and control arms. Chi square tests of independence were used to identify any characteristics
that differed significantly between the two study arms. The FCCM program decline rate was low
(<10%) and enrollment characteristics of children in FCCM and control sites were similar, thus
a simple chi-square test was used to compare the two proportions at 5 percent significance
level. An intention-to-treat analysis was performed in which all children at facilities offering the
FCCM program were compared to all children at facilities without the FCCM program. To identify
factors associated with viral suppression and undetectability, unadjusted bivariate and adjusted
multilevel logistic regression models were developed to estimate the association between viral
suppression and undetectable viremia, and putative factors in each study arm.
For the qualitative component, IDIs were audio recorded and transcribed in Microsoft Word, and
simultaneously translated into English, by research assistants who conducted the interviews.
The study team reviewed the transcripts and created a codebook based on the transcripts.
Maxqda software was used to store and code transcripts. After coding was complete, data
were summarized through descriptive, text-based summaries and tables by study investigators,

12 ■ Piloting and evaluating family-centered care in Eswatini

identifying themes and patterns in the data. Results are presented by group (caregivers and HW)
and summarized into overall findings.
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KEY FINDINGS
QUANTITATIVE FINDINGS
A total of 379 HIV-positive children under the age of 15 years (207 in the intervention arm and
172 in the control arm) from 363 unique families (203 in the intervention arm and 160 in the
control arm) were enrolled in the study from September 2017 to July 2019. Table 1 shows the
number of participants enrolled in the study by site and study arm. The unique families include
363 caregivers (97% living with HIV) and 28 other family members living with HIV (children and
adults) living in the same household as the child and caregiver.
Table 1 Prospective cohort enrollment
Facility name

Facility type

Study arm

Unique families
enrolled

Children
enrolled

Other family
members
enrolled

Pigg's Peak

Parent

Intervention

61

62

3

Horo

Filter clinic

Intervention

40

41

7

Emkhuzweni

Parent

Intervention

58

59

8

Mangweni

Filter clinic

Intervention

44

45

1

Dvokolwako

Parent

Control

56

61

3

Bhalekane

Filter clinic

Control

39

41

2

Mbabane

Parent

Control

33

34

3

Lobamba

Filter clinic

Control

32

36

1

363

379

28

Total

Table 2 shows demographic characteristics of children at enrollment. Nearly half of all children
(47%) were aged 5–9 years, one-third of children were aged 10–14 years and the rest were under
the age of 5 years. Among children over age five years, 93 percent were in school. Of the children
in school, 36 percent had missed school in the three months before enrollment; more children in
the control than intervention group had missed school.
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Table 2 Demographic characteristics of HIV-positive children at enrollment
Variable

Control
n=172
n (%)

Intervention
n=207
n (%)

Total
N=379
n (%)

p-value

0.43

Gender
Female

81 (47)

106 (51)

187 (49)

Male

91 (53)

101 (49)

192 (51)

8.1 (4)

8.6 (4)

8.4 (4)

0–<1

5 (3)

1 (.05)

6 (2)

1–<2

5 (3)

2 (1)

7 (2)

2–<5

27 (16)

35 (17)

62 (16)

5–<10

82 (48)

97 (47)

179 (47)

10–14

53 (31)

72 (35)

125 (33)

Age (years)
Mean (SD)

0.20

Child in school (n=133 control; n= 169 intervention)
Yes

125 (94)

155 (92)

280 (93)

No

8 (6)

14 (8)

22 (7)

0.45

Days missed school in past 3 months (n=125 control; n=155 intervention)
Did not miss

67 (54)

112 (72)

179 (64)

<7 days

58 (46)

39 (25)

97 (35)

7–14 days

0 (0)

3 (2)

3 (1)

15–30 days

0 (0)

1 (0.6)

1 (0.4)

0.001

Less than a third of children (28%) had ever been hospitalized. Most of the 106 children who
had ever been hospitalized (76%) had only been hospitalized once. Only six (6%) children had
been hospitalized three to five times. Since initiating HIV care, almost all children (98%) had been
continuously receiving care (Table 3, next page).
At enrollment, 160 (42%) of all children knew their HIV status. Figure 1 (next page) breaks
disclosure down by age group: 102/122 (84%) age 10–14 years knew their HIV status; 57/175
(33%) age 5–9 years knew their HIV status; and almost all children under the age of 5 years were
not aware of their HIV status.
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Table 3 HIV history of HIV-positive children at enrollment
Variable

Control
n=172
n (%)

Intervention
n=207
n (%)

Total
N=379
n (%)

p-value

0.24

Ever been hospitalized
Yes

51 (30)

55 (27)

106 (28)

No

121 (70)

149 (72)

270 (71)

Other

0 (0)

3 (1)

3 (0.8)

Number of hospitalizations (n=46 control; n=50 intervention)
1

35 (76)

38 (76)

73 (76)

2

9 (20)

8 (16)

17 (18)

3–5

2 (4)

4 (8)

6 (6)

202 (98)

373 (98)

0.55

After entering HIV care, child continually in care
Yes

171 (99)

No

1 (0.6)

4 (2)

5 (1)

Other

0 (0)

1 (0.5)

1 (0.3)

0.33

Child knows HIV status
Yes

83 (48)

77 (37)

160 (42)

No

83 (48)

127 (61)

210 (55)

6 (4)

3 (1)

9 (2)

207 (100)

378 (99.7)

0 (0)

1 (0.3)

Other

0.03

Child currently on ART (n=206 intervention)
Yes

171 (99)

No

1 (0.6)

NS

Figure 1 Children’s awareness of HIV status by age and group at enrollment
Control

Intervention

Total

89%

Percent of children

76%

82%

48%

43%

37%

32%
23%
3%
1%
0%
0–5 years

5–<10 years

10–14 years
Age
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All ages

42%

All children were receiving ART at enrollment except one child. Figure 2 shows ART regimen
type for children at enrollment. The majority of children were on zidovudine (AZT)+lamivudine
(3TC)+nevirapine (NVP) (39%). Other regimens included, abacavir (ABC)+3TC+lopinavir/ritonavir
(LPV/R) (19%), ABC+3TC+efavirenz (EFV) (17%), AZT+3TC+LPV/r (10%) and AZT+3TC+EFV (6%).
In the year before enrollment, 30 percent of children had reported treatment interruptions.
Figure 2 Treatment regimen for children receiving ART at enrollment
AZT+3TC+NVP

ABC+3TC+LPV/r

ABC+3TC+EFV

Control group (n=171)
n=21
12%

AZT+3TC+LVP/r

Intervention group (n=207)

n=17
10%

n=37
22%

n=19
12%

n=33
16%

n=28
14%

n=58
34%

n=87
42%

n=40
19%

n=38
22%
ABC+3TC+NVP n=6
AZT+3TC+EFV9 n=9
TDF+3TC+EFV n=1
TDF+3TC+LPV/r n=1

Other

Mean age child by regimen type
EFV regimen, mean age 10.3 yrs
NVP regimen, mean age 9.3 yrs
LVP/r regimen, mean age 5.5.yrs

ABC+3TC+NVP n=10
AZT+3TC+EFV n=16
TDF+3TC+EFV n=5

At enrollment, 60 percent of children were adhering well (>95% doses) to their ART regimen,
with only 6 percent with poor adherence (<85%) (Figure 3, next page). In the last 7 days before
enrollment, 10 percent of children had missed their ART drugs at least once. A total of 85 percent
of children had their last two ART refill pick-ups on time.
At enrollment, 78 percent of children had achieved viral suppression (<1,000 copies/mL) (80%
intervention and 77% control, p=0.68) and 74 percent of children had undetectable viremia
(<400 copies/mL) (76% intervention and 72% control, p=0.51). Factors associated with viral
suppression at enrollment were child’s age and ART regimen. Viral suppression was most likely
among older versus younger children, with 82 percent in children aged 10–14 years; 80 percent
in children aged 5–9 years; 74 percent in children aged 2–5 years; and 46 percent in children
under age 2 years. Viral suppression was higher among those children on EFV-based regimen
(87%) compared to NVP-based regimens (73%) and LPV/r-based regimens (79%).
Of the 363 caregivers who enrolled in the study, 92 percent were women (Table 4, next page).
Women caregivers were significantly younger than men caregivers (mean age (min, max): 35
(15–73) versus 40 (27–67) years. About half of the caregivers were married or living together
as a couple, 33 percent had never been married, 11 percent were widowed and 3 percent were
divorced.

Figure 3 Child’s ART adherence at enrollment
Intervention (n=207)

Control (n=171)

p=0.46
n=144 n=176
84% 85%

Percent of children

p=0.012

n=91
54%

n=137
66%

p=0.18
n=50 n=62
30% 30%

n=52
30% n=46
22%

p=0.49
n=10 n=9
6% 4%
Spent more than Treatment
2 days without interruptions
(past year)
treatment
(past month)
Unknown/NA
27

Good
adherence

n=13 n=18
8% 9%

n=15
9% n=6
3%

Moderate
adherence

Poor
adherence

Unknown
adherence

Current ART adherence

Unknown
9

Unknown
98

7

Last 2 drug
pick-ups on time

Table 4 Caregiver demographic characteristics at enrollment
Variable

Control
n=160
n (%)

Intervention
n=203
n (%)

Total
N=363
n (%)

p-value

35 (15-70)

36 (21-73)

35.5 (15-73)

NS

147 (93)

186 (92)

333 (92)

0.77

13 (8)

17 (8)

30 (8)

Age (years)
Median (range)
Gender
Female
Male
Education
Never attended

20 (13)

31 (15)

51 (14)

Primary

67 (42)

68 (34)

135 (37)

Secondary

59 (37)

71 (35)

130 (36)

Beyond secondary

14 (9)

33 (16)

47 (13)

65 (41)

95 (47)

160 (44)

9 (6)

12 (6)

21 (6)

Single

60 (38)

59 (29)

119 (33)

Divorced/Widowed/Separated

26 (16)

37 (18)

63 (17)

0.22

Marital status
Married
Living with partner

0.45

Nearly all of the caregivers (97%) were living with HIV at enrollment (Table 5). About 41 percent of
caregivers’ households had more than one adult living with HIV, and 10 percent had more than
one child living with HIV in the household.
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Table 5 Caregiver HIV history at enrollment
Variable

Control
n=160
n (%)

Intervention
n=203
n (%)

Total
N=363
n (%)

p-value

Positive

153 (96)

198 (98)

351 (97)

0.31

Negative

7 (4)

5 (3)

12 (3)

HIV status

Number of HIV+ adults in caregiver household including caregiver
0

4 (3)

2 (1)

6 (2)

1

87 (54)

122 (60)

209 (58)

2+

69 (43)

79 (39)

148 (41)

1

143 (89)

184 (91)

327 (90)

2

13 (8)

16 (8)

29 (8)

3–4

4 (3)

3 (2)

7 (2)

0.55

Number of HIV+ children in caregiver household
0.56

Number of HIV+ members on ART in caregiver household including caregiver and child
1

88 (55)

121 (60)

209 (57)

2

61 (38)

71 (35)

132 (36)

3+

11 (7)

11 (5)

22 (6)

0.74

All caregivers living with HIV were receiving ART at enrollment (Figure 4). At enrollment, 62
percent of caregivers were receiving tenofovir disoproxil fumarate (TDF)+3TC+EFV, 21 percent
were on AZT+3TC+NVP, and the rest were on other regimens. Most caregivers receiving ART were
on EFV-based regimens, 25 percent were on NVP-based regimens, and 4 percent were on LPV/Rbased regimens with NRTI backbones of ABC, AZT, or TDF plus 3TC.
Figure 4 ART regimen of caregivers at enrollment
TDF+3TC+EFV

Control group (n=151)

n=7

n=18
9%

4%

ABC+3TC+EFV n=1
TDF+3TC+NVP n=6
d4T+3TC+NVP n=1

AZT+3TC+EFV

Other

Intervention group (n=197)

n=18
12%

n=27
18%

AZT+3TC+NVP

n=99
66%

AZT+3TC+LVP/r n=4
TDF+3TC+LVP/r n=3
d4T+3TC+LVP/r n=3

n=18
9%

n=45
23%

ABC+3TC+EFV n=1
TDF+3TC+NVP n=8
AZT+3TC+FTC n=1

n=116
59%

AZT+3TC+LVP/r n=3
TDF+3TC+LVP/r n=3
ABC+3TC+LVP/r n=2
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Viral suppression among HIV-positive children during study
The total number of children with viral load test results decreased over time from 375 (100%),
337 (90%), 346 (84%), and 216 (58%) at enrollment, 6, 12, and 18 months, respectively, with
no significant difference between study groups. There was no statistically significant difference
in viral suppression or detectability by study arm at 12 or 18 months. Overall, viral suppression
improved between enrollment and 12 months follow up in both arms, from 78 percent at
enrollment (80% intervention, 77% control) to 90 percent at 12 months (89% intervention, 92%
control); and was 87 percent at 18 months (91% intervention, 83% control). The overall proportion
of children who achieved undetectable viral load increased from 74 percent at enrollment (76%
intervention, 72% control) to 87 percent at 12 months (88% intervention, 86% control) and 84
percent at 18 months (86% intervention, 82% control).
Table 6 Viral suppression among HIV-positive children during the study
Variable

Control
n=172
n (%)

Intervention
n=207
n (%)

Total
N=379
n (%)

p-value

HIV RNA <1,000 copies/ mL

130 (77)

164 (80)

294 (78)

0.41

HIV RNA ≥1,000 copies/mL

40 (24)

41 (20)

81 (22)

HIV RNA <1,000 copies/ mL

120 (92)

165 (89)

285 (90)

HIV RNA ≥1,000 copies/mL

11 (8)

20 (11)

31 (10)

HIV RNA <1,000 copies/ mL

88 (83)

100 (91)

188 (87)

HIV RNA ≥1,000 copies/mL

18 (17)

10 (9)

28 (13)

HIV RNA <400 copies/ mL

122 (72)

155 (76)

277 (74)

HIV RNA ≥400 copies/ mL

48 (28)

50 (24)

98 (26)

HIV RNA <400 copies/ mL

113 (86)

163 (88)

276 (87)

HIV RNA ≥400 copies/ mL

18 (14)

22 (12)

40 (13)

HIV RNA<400 copies/ mL

87 (82)

94 (86)

181 (84)

HIV RNA ≥400 copies/ mL

19 (18)

16 (15)

35 (16)

Viral suppression at enrollment

Viral suppression at 12-month follow-up
0.48

Viral suppression at 18-month follow-up
0.08

Undetectable viremia at enrollment
0.40

Undetectable viremia at 12-month followup
0.63

Undetectable viremia at 18-month followup
0.50

Among the 252 children who had viral suppression at enrollment, 97 percent remained
suppressed at 12 months follow up (98% intervention, 95% control, p=0.23); and 62 percent of
children who were unsuppressed at enrollment achieved viral suppression at 12 months follow
up (54% intervention, 75% control, p=0.10); there were no significant differences between study
groups (Table 7).
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Table 7 Viral suppression in children at 12- and 18-month follow-up by viral suppression status
at enrollment
Variable

Control
n (%)

Intervention
n (%)

Total
n (%)

Among children suppressed at enrollment, viral suppression at 6-month follow-up
HIV RNA <1,000 copies/mL

108/113 (96%)

143/150 (95%)

251/263 (95%)

Among children not suppressed at enrollment, viral suppression at 6-month follow-up
HIV RNA <1,000 copies/mL

14/31 (45%)

14/40 (35%)

28/71 (39%)

Among children suppressed at enrollment, viral suppression at 12-month follow-up
HIV RNA <1,000 copies/ mL

101/106 (95%)

143/146 (98%)

244/252 (97%)

Among children not suppressed at enrollment, viral suppression at 12-month follow-up
HIV RNA <1,000 copies/mL

18/24 (75%)

20/37 (54%)

38/61 (62%)

Factors associated with viral suppression and undetectable viremia
In unadjusted bivariate analyses among all children at 12 months after enrollment, several
factors were significantly associated with viral suppression (HIV RNA <1,000 copies/mL). Children
who were not aware of their HIV status tended to be less likely than children who were aware
of their HIV status to be virally suppressed (OR:0.46; 95% CI: 020, 1.08). Compared to children
with caregivers under age 25 years, children with older caregivers aged 30–40 years (OR: 5.53;
95% CI: 1.80, 17.00) and aged >40 years (OR: 3.93; 95% CI: 1.30, 11.85) were significantly more
likely to be suppressed. Most caregivers were living with HIV, with only 12 caregivers being HIVnegative. The odds of suppression among children with HIV-negative caregivers were significantly
lower than the odds of suppression among children with HIV-positive caregivers (OR: 0.15; 95%
CI: 0.05, 0.49). At study entry, children on NVP-based ART had significantly lower levels of viral
suppression (73%) than those on EFV-based (87%) or LPV/r-based ART (79%) (p=0.04). While
rates of viral suppression at 12 months after enrollment remained lowest in those on NVPbased ART (87%) compared to EFV-based ART (94%) and LPV/r-based (91%) ART, this was not
statistically significant (p=0.31). Study intervention versus control group was not statistically
significantly associated with viral suppression at 12 months (p=0.48) or 18 months (p=0.08)
after enrollment.
In unadjusted bivariate analyses among all children at 12 months, similar factors were associated
with undetectable viremia (HIV RNA <400 copies/mL). The odds of undetectable viremia tended
to be lower among children who did not know their HIV status compared to children who did know
their HIV status (OR: 0.55; 95% CI: 0.26, 1.14, p=0.10). Children in the care of older caregivers
aged 30–40 years (OR: 5.24; 95% CI: 1.83, 15.04) and older than 40 years (OR:3.15; 95%
CI:1.14, 8.68) were more likely to have undetectable viremia than children in the care of younger
aged caregivers aged under 25 years. Children in the care of HIV-negative caregivers versus HIVpositive caregivers were less likely to have undetectable viremia (OR:0.15; 95% CI: 0.05, 0.46).
The odds of undetectable viremia were significantly lower among children in households with
three or more HIV-positive children versus children in households with two or fewer HIV-positive
children (OR: 0.21; 95% CI: 0.06, 0.78). Although undetectable viremia at 12 months after
enrollment was lowest among children on NVP-based ART (84%) compared to EFV-based (90%)
and LPV/r-based (89%) ART, this was not statistically significant (p=0.38). Study intervention
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versus control group was not statistically significantly associated with undetectable viremia at 12
months (p=0.63) or at 18 months follow (p=0.38).
There was an association of age with suppression and undetectable viral load. Overall, 93 percent
of children aged 10–14 years had viral suppression at 12 months follow up compared with 88
percent of children aged 5–9 years and 76 percent of children aged under 5 years. Similarly,
undetectable viral load was observed in 91 percent of children aged 10–14 years, 87 percent of
those aged 5–9 years, and 81 percent of those aged under 5 years. There was not a significant
difference in the levels of suppression or detectability by intervention versus control group when
stratified by age.

Retention in care, adherence, interruptions in ART care, and HIV
disclosure
There were no significant differences between intervention and control groups in retention in care,
interruption of ART, or reported adherence or disclosure at 12 months (Table 8). At 12 months
of follow-up, 93 percent of children expected to be seen at the 12-month visit had a documented
clinic visit, with no significant difference between groups (91% intervention, 94% control,
p=0.53). At the 12-month visit, ART interruption was reported by 16 percent in the intervention
and 15 percent in the control groups (p=0.82); good adherence was reported by 84 percent in
the intervention and 87 percent of the control groups (p=0.32); and last two drug pick-ups were
reported to be on time for 88 percent of intervention and 92 percent of control group children
(p=0.18). The proportion of children who did not know their HIV status at enrollment but learned
their HIV status during the study was low and not statistically different between groups (6%
intervention and 5% control. p=0.69). In the more limited sample of 216 children with 18-month
follow-up, 12 percent reported ART interruption, 93 percent reported good ART adherence, and
87 percent reported last two drug pick-ups were on time, with no significant differences between
groups.
Table 8 Retention, adherence, and disclosure for children living with HIV during the study
Variable

Control
n (%)

Intervention
n (%)

Total
n (%)

p-value

152/161 (94)

178/195 (91)

330/356 (93)

0.31

12-month visit retention
Number with clinic visit/number
expected for visit
12-month visit ART adherence*
ART interruption since last visit

19/131 (15)

26/168 (16)

45/299 (15)

0.82

Good reported adherence

95/109 (87)

102/121 (84)

197/230 (86)

0.32

134/145 (92)

153/174 (88)

287/319 (90)

0.18

4/79 (5)

8/125 (6)

12/204 (6)

0.69

Last 2 drug pick-ups on time
New disclosure during study**
New HIV disclosure to children who
did not know status at enrollment

*Data missing for ART interruption for 55/354 (16%) children (30/161 control, 19%; 25/193 intervention, 13%); ART adherence
124/354 (35%) children (52/161 control, 32%; 72/193 intervention, 37%); and drug pick up for 35/319 (11%) children
(16/161 control, 6%; 19/193 intervention, 10%)
**Data on child disclosure status at enrollment were available for 370/379 (98%) children, with 210 undisclosed; data on
subsequent disclosure were available for 204/210 (97%) (79/83 control, 95%, and 125/127 intervention, 98%)
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QUALITATIVE FINDINGS
In this section of the report, key findings from semi-structured interviews with caregivers and
health workers engaged in the FCCM program are presented. Key themes are described in the
following order: demographic characteristics of caregivers and HWs, benefits of FCCM, challenges
in participating in FCCM and in implementation, and recommendations for improving the FCCM
model in the Eswatini context.

Characteristics of semi-structured interview participants
Table 9 Caregiver demographic characteristics
Semi-structured interviews were conducted
Variable
Caregivers
with 25 caregivers participating in the FCCM
n=25
program in four intervention sites. Table 9
n (%)
presents caregiver demographic data. Of
Age (years)
Mean = 37.8
the 25 caregivers, only two were men, most
(26–63)
were married or cohabitating (17 of 25),
Gender
and the mean age was 37.8 years. The child
Female
23 (92)
and caregiver were the only family members
Male
2 (8)
enrolled in the FCCM program in 19 of the 25
Education
caregiver households, and 16 caregivers were
Primary and lower
12 (48)
the biological parent of the child. All of the
Beyond
primary
13 (52)
caregivers and their children were HIV-positive
and on ART at the time they were interviewed for Marital status
the study.
Never married
8 (32)
Married, non-polygamous

10 (40)

Married, polygamous

4 (16)

Cohabitating

3 (12)

Employment status
Unemployed

19 (76)

Employed

6 (24)

Relationship to child
Biological parent

16 (64)

Number of HIV-positive family
members enrolled in FCCM
2 (caregiver and child)

19 (76)

3+

6 (24)

Child currently on ART

25 (100)

Caregiver currently on ART

25 (100)
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A total of 17 health workers were interviewed for the Table 10 Health worker characteristics
FAM-CARE study; their demographic data are shown
Variable
Health worker
n=17
in Table 10. Most of the HWs were women (14 of 17)
n (%)
and had some secondary education (12 of 17). Most
Gender
common roles of the HWs interviewed were midwife
Female
14 (82)
or expert client.
Male

Benefits of FCCM

3 (18)

Education
Secondary

2 (12)

Caregivers said that they felt that FCCM
High school
1 (6)
strengthened the family bond. FCCM was perceived
Tertiary
14 (82)
as encouraging family members to disclose their
Current role in health facility
HIV status to other family members, including to
Midwife
6 (35)
male partners and the child. Caregivers said they
Expert client
6 (35)
felt this helped to reduce stigma within the family
Nursing
sister
2 (12)
by encouraging family members to talk more openly
Senior nurse
1(6)
about living with HIV and taking ARV drugs. If one
family member forgets to take their medication,
General nurse
1(6)
another family member can remind them. Caregivers
Nursing assistant
1(6)
also viewed their disclosure with their children
as a positive way for the child to see that the caregiver is also living with HIV and taking their
medication, motivating the child to continue to participate in FCCM and take their medication.
Caregivers said that for some men, participating in FCCM helped them in their caregiver role and
to support women and children in the family in HIV care and treatment.

“

Another thing is that there is no more hiding from each other to take pills on time.
Even my child is always reminding us that it is now time to take pills so we do things
together. No one to say, eish…now it is time for medication, the child also knows the dates.
Even in January the child will come again for the next visit. The family is always free to do
things together. It is like a game to us now because we are happy.
—Female caregiver, age 29, of boy age 8

Caregivers also viewed FCCM as having practical benefits in saving time. Caregivers liked the “fast
tracking” where, as participants in FCCM they were moved to the front of the line. This reduced
time at the facility typically spent waiting in line.

“

… I am now more comfortable unlike before when I would think of going to the
facility, I would first think of the long lines and would be irritated in one way or the
other. The FCCM patients are the ones provided with services first, and they always tell us
to come early in the morning as we are the first clients to be taken care of.
—Female caregiver, age 43, of boy age 13

Caregivers’ perceived the FCCM program to offer better counseling than the counseling
provided in the standard of care, and that HWs in FCCM were taking “good care” of them.
Patient files in FCCM were viewed by caregivers as being kept more confidentially than in the
standard of care. Caregivers liked that FCCM provided call reminders for upcoming visits and
the fact that they saw the same HW at each clinic visit.
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“
“

When I used to come before I was enrolled in FCCM they would just count my pills,
but now when I come I would always talk to a nurse in a certain room [who would]
ask me how do I feel, how is the child doing on his treatment. Then that would make me
feel happier to get such a warm welcome from a health care worker.
—Female caregiver, age 28, of girl age 7

And what I like with FCCM program is that, if there is one member who doesn’t drink
the medication or doesn’t adhere, the HW are able to correct our mistakes, motivate
us and encourage us together as a family.
—Male caregiver, age 40, of girl age 13

HWs said the FCCM program enabled them to gather and track family histories, identify family challenges to HIV care and treatment, and identify long-lasting solutions. HWs said FCCM
facilitated communication among family members, encouraging individuals to share more of
their needs together with other family members. Meeting with caregivers and their children
together provided an opportunity for HWs to assist caregivers in disclosing their HIV status
to the child. HWs liked having patient files for each family pulled ahead of time and grouped
together for the clinic visit.

“

Addressing them as a family is much better because everyone will say their side they
want to talk about, they don’t talk about each other. When they are together there
will be some transparency. They will be able to talk to each other. It has also helped us with
disclosure, even if the mother was scared to tell the child, they can now tell the child as a
family.
—Female health care worker, age 37

HWs said FCCM improved the patient-provider communication and relationship, where patients could ask questions of providers and were more actively seeking information during
clinic visits.

Challenges in FCCM
Caregivers had to incur additional costs for clinic visits for multiple family members, as FCCM
required the family to visit the clinic together. There were schedule conflicts with clinic visits for
school-aged children attending school and weekend teen support groups. It was also difficult for
some caregivers to encourage men in their families to participate in FCCM because men did not
want to get an HIV test. Caregivers also said that sometimes in the facility when they could step to
the front of the line as part of the “fast tracking” of FCCM participants, other clients in the waiting
room criticized them and complained.
At some facilities, HWs said that some families did not attend clinic visits together as a family
unit. Some families rotated family members to come pick up medication for the whole family. HWs
also noted that some families were food insecure and children would skip taking their medication
because taking it on an empty stomach made them feel sick.
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HWs also had challenges with managing larger groups of family members at the same time and
experienced staff shortages. HWs said sometimes family members did not get along and this
was difficult to manage. When there were larger groups and staff members were seeing multiple
clients at one time, the clinic visits took longer, and some facilities did not have enough staff to
cover the visits.
While caregivers said FCCM encouraged disclosure, many HWs saw disclosure as a challenge of
implementing FCCM. Disclosure in the context of the family was difficult for many family members
because of the fear of what other family members or partners would think of them and fear of
family members gossiping about them to others. Many children were not aware of their HIV status
because caregivers were unable to fully disclose the child’s status.

“
“

As the disclosure has been a problem, parents were anxious on how they will tell
their children… they cannot disclose well.
—Female health care worker, age 54

But then the challenge that I have is that my son keeps asking me when will he stop
taking the pills? He always says that he is tired of taking the pills, the child further
says that he is not sick, he feels better now.
—Female caregiver, age 28, of boy age 10

In particular, both HWs and caregivers said that encouraging men to participate in FCCM was a
challenge. Some men were hesitant to receive HIV testing and counseling as part of the FCCM
program. Both caregivers and health workers mentioned difficulty in discussing sensitive health
information in the presence of other family members. For HWs, it was a challenge to ask sensitive
questions, such as asking adolescents about their sexual activity in the presence of their
caregiver or asking caregivers about reproductive health and family planning use in front of their
children.

Recommendations for FCCM strengthening and scale-up
Most participants felt that the FCCM program should be continued and scaled-up nationally. The
FCCM program was well-liked by participants, who thought the program should continue and
should be expanded to other communities. Scale-up was recommended by participants because
they perceived the program provided benefit in reducing stigma within the family and promoted
more open discussion about HIV and HIV disclosure within the family. Participants said that the
encouragement to disclose helped family members support one another in adherence to ART and
clinic appointments. For some families, FCCM saved money in transport costs in attending clinic
visits.
HWs stated they would like more training on how to ask sensitive questions within the context of
a family clinic visit and how to offer counseling to caregivers to disclose their HIV status to family
members and to children, and to disclose the child’s HIV status to the child. HWs also wanted
more training in how to manage family dynamics and what to do if family members do not get
along.
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HWs suggested adding a social worker to the FCCM provider team to address psychosocial needs
of families in HIV care and treatment. The FCCM does not currently include a social worker. To
address the additional work burden and extended time of the clinic visit for HWs to see multiple
family members in one visit, HWs suggested increasing the number of staff at the facility on
FCCM clinic days.
Caregivers and HWs suggested designating specific days for FCCM clients only, to reduce the
amount of time FCCM clients wait in line if they are not “fast tracked” to the front. Both caregivers
and HWs also suggested preparing the families’ medications ahead of the clinic visit so family
members do not have to wait in long pharmacy lines to receive their medication.
Another suggestion was to offer other types of care such as screening tests for blood sugar levels
or taking care of other health concerns such as head or stomach pain, during the FCCM clinic
visit. Seeing the same nurse at each visit and adding more FCCM staff with specific roles and
responsibilities were suggested by both caregivers and HWs for improving service delivery. HWs
reported an increased work burden to provide care to families rather than to individual clients
during clinic visits. The FCCM clinic visits take longer and some HWs said their facility did not
have sufficient staff to cover these longer visits and attend other clients; thus, adding staff for
FCCM programming would improve wait times during the FCCM clinic visits.
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DISCUSSION
The study arm was not significantly associated with viral suppression or undetectable viremia at
12 (or 18) months after enrollment. Participation in FCCM did not show any statistically significant
improvements in retention, adherence, ARV drug refill pick-ups, or children who knew their HIV
status versus control groups. In the control arm, high proportions of children had achieved viral
suppression, retention, and adherence. In order to detect a difference in these outcomes, a
significantly larger sample size would have been required.
Analysis of enrollment data demonstrated that factors associated with lack of viral suppression
included younger age (<5 years) and treatment regimen, with children receiving NVP-based ART
significantly less likely to have viral suppression. When children are on a suboptimal regimen, they
are less likely to achieve viral suppression. These results highlight the importance of programs
in Eswatini and elsewhere to monitor treatment regimens as children age and ensure WHO
guidelines for treatment regimens are implemented to optimize pediatric outcomes. Following
mid-study analysis of enrollment data demonstrating that a significant proportion of children
were receiving suboptimal ART, EGPAF developed a briefing sent to all EGPAF countries regarding
the need to review and optimize ART regimens in all children (Appendix 6). These data were also
published in Pediatric Infectious Disease Journal to get wider dissemination of the critical need
to continually review ART regimens to ensure optimization of ART in children as they age up
(Chouraya et al. 2019)
Caregivers and HWs involved in FCCM discussed both benefits and challenges of FCCM in
qualitative interviews. Caregivers perceived improved adherence, retention in care, and overall
health of children in the program. HWs said FCCM encouraged HIV disclosure and support for
adherence among family members. However, HWs said that timing of teen support groups and
school schedules were not coordinated well with clinic visits. There was a lack of fidelity to the
FCCM model noted, with some sites reporting that families did not attend clinic visits together as
a family, but rotated family members to come get medication for the whole family. Both caregivers
and HWs had difficulties in discussing sensitive health information in the presence of other family
members. According to FCCM program data, only 40 percent of all 465 families enrolled in the
program at the pilot sites actually attended at least one clinic visit together as a family, and only
26 percent of families attended clinic visits together four times a year. Attendance at FCCM was
not related to age of the child; similar proportions of families with a child under 10 years of age
(42%) versus with a child at least 10 years of age (38%) attended at least one clinic visit together
as a family. Families enrolled in FCCM with only two members living with HIV (e.g., caregiver and
child) were more likely to have attended at least one clinic visit as family than those with more
than two family members living with HIV (47% versus 20%, respectively).
Results from the quantitative data reflect the challenges discussed in qualitative interviews. One
of the challenges of participating in FCCM was schedule conflicts with school and teen support
groups. Because of these challenges, caregivers with older children may have been less likely to
attend clinic visits with their child than caregivers with younger children. Both HWs and caregivers
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said they had difficulty discussing sensitive health information in the presence of other family
members. For older children and their caregivers, these factors may have been more of a barrier
to attend clinic visits together than caregivers with younger children. However, children aged at
least 10 years had the highest rates of viral suppression compared to younger children; 12-month
suppression was 94 percent and undetectable viral load was 91 percent. Understanding the
role of teen support groups in improving viral suppression and adherence among adolescents
compared to FCCM or similar family-centered care models would be helpful. While this suggested
to us that perhaps FCCM may be most effective among the younger children, when doing a
stratified analysis by age under 5 years, 5–9 years and more than 10 years, there did not
appear to be a differential effect of FCCM on viral suppression by age, with suppression and
undetectability not significantly different between FCCM and control children, regardless of age.
Children who did not know their HIV status tended to be in the care of younger caregivers and
have HIV-negative caregivers and were less likely to achieve viral suppression at 12 months
after enrollment. Supplemental training for health providers engaged in FCCM in how to support
caregivers in disclosing the child’s HIV status could improve the proportion of children who know
their HIV status, a need specifically noted by HWs in the qualitative component of the study.
Adolescent or young adult caregivers may need additional support in caring for children living
with HIV, including administration of the recommended ART regimens, adhering to clinic visit
schedules, and HIV disclosure to the child. Providers may need additional training in counseling
and identifying the needs of younger caregivers to be able to effectively support and counsel
them. The complex psychosocial needs identified by HWs who participated in semi-structured
interviews and their recommendation to have social workers added to the care team reflects an
important gap in adequately addressing structural and social barriers within the family that can
affect HIV outcomes for children.
PEPFAR guidance stipulates that “differentiated care and innovative service delivery (DSD)
models should focus on populations that have difficulty with retention, such as children,
adolescents, young adults, men, pregnant women, and key populations. Adherence programs
should be focused on the clients with elevated viral loads and not generic programs to all clients.”
The FCCM program is considered a DSD service delivery model for children and families. One
of the lessons learned through implementing the FCCM is that children older than 10 years
prefer peer to peer support through the teen support groups rather than being accompanied
by caregivers to clinic appointments. The model is also helpful for those on treatment failure
(caregivers and children) to better monitor and counsel caregivers and children in adherence.
Drug dispensing should be aligned to the extent possible for stable caregivers and children so
that they are able to attend FCCM visits on the same schedule. These lessons learned align with
PEPFAR guidance on DSD and multi-month dispensing of medication.

LIMITATIONS

There are several limitations to the study. Given slower than expected enrollment, the overall
sample size was lower than planned (379 versus 444). Slow enrollment resulted in reducing
the follow-up time from 18 to 12 months in order to adhere to the study timeline, with only 57
percent of children followed for the full planned 18 months, limiting the power of the study to
detect differences between study arms for children over time. Additionally, given the high levels
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of viral suppression, retention, and adherence at baseline in both FCCM and control children, it
would have required a significantly larger sample size to be able to detect a difference in these
outcomes with the FCCM program.
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CONCLUSION AND
RECOMMENDATIONS
CONCLUSIONS
Children had high levels of viral suppression and undetectable viremia at enrollment, which
further improved by 12 months after enrollment, with no significant differences between FCCM
intervention and control groups. Factors associated with viral suppression at 12 months after
study entry included child’s awareness of their HIV status, caregiver’s age, and caregiver’s HIV
status, with similar factors associated with undetectable viremia.
Enrollment data demonstrating that a significant proportion of children were receiving suboptimal
NVP-based ART, which was associated with lower levels of viral suppression, were important to
direct attention to the critical need to review and optimize ART regimens in all children as they
age up and more potent and less toxic regimens may become available.
Overall, caregivers and health workers who participated in semi-structured interviews liked the
FCCM program and valued the services received through the program. Caregivers felt FCCM
promoted disclosure to other family members, reducing HIV stigma and encouraging adherence
support for each other. Caregivers perceived FCCM as improving both ART adherence and
retention in care, as well as the overall health of the child. HWs viewed FCCM as improving
patient-provider communication and facilitating tracking patient histories. Challenges were also
discussed. Caregivers reported scheduling conflicts with school schedules and teen support
group meetings. HWs noted poor fidelity to the FCCM intervention, with some families not
attending clinic visits together as a family as a whole, but rather rotating family members to
come to the facility to pick up medication for all family members. Both caregivers and HWs had
difficulties with sharing sensitive health information in the presence of other family members.
Given the favorable view by caregivers and HWs, the government of Eswatini plans to implement
the FCCM as one of the DSD models for HIV care for families. These findings highlight important
considerations for improving pediatric HIV care as well as FCCM programs for younger-aged
caregivers and HIV-negative caregivers, and for HWs in supporting caregivers in disclosing HIV
status to children. Given the high rates of suppression in older children, evaluation of the effects
of teen support clubs on HIV pediatric outcomes could illuminate how sufficient teen support
groups are in ensuring ART adherence and viral suppression among older children. Based on
these findings, specific recommendations are provided here for consideration in planning for
national scale up of FCCM in Eswatini. These findings and recommendations may apply to similar
country contexts in sub-Saharan Africa.

Piloting and evaluating family-centered care in Eswatini ■ 31

RECOMMENDATIONS
As the Eswatini Ministry of Health plans for FCCM program scale up, several important
recommendations based on these study findings could improve program implementation and
thus achieve better pediatric HIV outcomes. These recommendations would be able to improve
implementation of the FCCM program and are also relevant to pediatric HIV care in general:
y Continue to ensure access to treatment regimen and viral load monitoring in order to optimize
pediatric treatment regimens.
y Provide additional training to health providers in counseling and support to caregivers for HIV
disclosure to the child and to other family members.
y Provide additional counseling and support for younger caregivers (<25 years of age) with
children in HIV care and treatment.
y Provide additional support to caregivers who have younger children in HIV care and treatment,
where rates of viral suppression are lower.
y Revise the FCCM SOPs and programming to aid implementation with fidelity:
 Improve coordination of the timing of FCCM clinic visits for school-aged children to better
accommodate school and teen support group schedules.
○ FCCM is most appropriate for children younger than age 10 years and their caregivers, and
for caregivers and children experiencing treatment failure. Children 10 years and older
benefit more from peer to peer support through the teen support clubs.
○ Disclosure is only assessed once during the clinic visits, at enrollment. Disclosure should
be assessed at different time points along the cascade as the child’s understanding of their
HIV diagnosis changes over time.
○ At enrollment see all family members, conduct baseline assessment to ascertain if families
need frequent monitoring or less.
○ For stable families, visits can be scheduled quarterly aligning with school holidays.
○ Align caregiver and child’s schedule for drug dispensing for stable patients, and advocate
and mentor health care workers to offer multiple month refills for children.
○ Ensure the number of families with appointments are manageable in a day. Family
appointments should be distributed across several days as opposed to all families visiting
health facilities on a single day. Appointments should be based on family sizes.
 Include additional training for health providers in counseling and talking to adults about
sensitive health topics in the context of the family and in managing larger groups during clinic
visits.
 Add social workers to the FCCM care team to address psychosocial needs of program
participants.
• Evaluate the effects of teen support groups on ART adherence and viral suppression in older
children.
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APPENDICES
APPENDIX 1
SCHEMA OF STUDY DESIGN FOR THE EVALUATION OF
FAM-CARE PROGRAM DESIGN
Four clusters of health care facilities/clinics in Hhoho Region Eswatini
Two hospital-based clusters with their filter clinics and two health cetner-based
clusters with their filter clinics

Random selection of clusters (stratified by whether health center vs hospital
cluster) to implement family-centered model or continue standard of care

Randomized cluster selection
for implementation

FAMILY-CENTERED CARE MODEL IMPLEMENTATION
Emkhuzweni Health Center cluster
Three filter clinics
Pigg’s Peak Hospital cluster
Ten filter clinics

CONTROL STANDARD OF CARE CONTINUED
Dvokolwako Health Center cluster
Four filter clinics
Mbabane Hospital cluster
Twelve filter clinics

Study Arm 1 Cohort Enrollment
(Intervention—Family-Centered Care)
Emkhuzweni Health Center
Mangweni Clinic
Pigg’s Peak Hospital cluster
Horo Clinic

Study Arm 1 Cohort Enrollment
(Control Standard of Care)
Dvokolwako Health Center cluster
Balekane Nazarene Clinic
Mbabane Hospital cluster
Lobamba ART Clinic

Enroll HIV-positive child <15 years
• Receiving ART (endpoints: viral load
suppression/HIV RNA >1,000 c/mL; pattern of
retention)
• Not receiving ART (endpoints: ART initiation;
viral suppression/HIV RNA >1,000 c/mL;
pattern of retention)
Follow-up: 12 months (originally 18 months)

Enroll HIV-positive child <15 years
• Receiving ART (endpoints: viral load
suppression/HIV RNA >1,000 c/mL; pattern of
retention)
• Not receiving ART (endpoints: ART initiation;
viral suppression/HIV RNA >1,000 c/mL;
pattern of retention)
Follow-up: 12 months (originally 18 months)
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APPENDIX 2
DATA COLLECTION ACTIVITIES
Enrollment

Data collection

Months
3

6

9

12

15

18

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

X

All children living with HIV
Demographic data

X

HIV and ART history

X

Current ART regimen (regimen,
adherence, drug pick-up)

X

Interim (between visits) HIV history
CD4 count (medical chart abstraction)

X

Medical visit attendance timeliness/
missed visits
Viral load test (drawn for study)

X

X

X

X

Caregivers and other family members
living with HIV
Demographic data

X

Family HIV history

X

HIV+ caregiver ART and viral load
history (interview and medical chart
abstraction)

X

HIV+ family member ART and viral
load history (interview and medical
chart abstraction)

X

X
X

X

X

X

X

X

X

X

X

*Collected any time a child was initiated on ART (on ART at entry or starts ART during study)

APPENDIX 3
IDIS CONDUCTED IN EACH FAM-CARE PROGRAM SITE
Facility name

Facility type

Facility
ownership

Number of caregivers
interviewed

Number of HWs
interviewed

Pigg’s Peak Government

Hospital

Public

9

7

Horo

Clinic

Public

5

3

Emkhuzweni

Health center

Public

7

5

Mangweni

Clinic

Public

4

2

25

17

Total

36 ■ Piloting and evaluating family-centered care in Eswatini

APPENDIX 4
FIVE STEPS IN PROVIDING FCCM FROM FCCM STANDARD
OPERATING PROCEDURES (SOP)
1. Sensitization of clients about FCCM
The expert clients, HTS counselors, and nurses included FCCM during the health talks in the
morning and during one-on-one counseling using FCCM sensitization script.
2. Enrollment into FCCM
Expert clients identified eligible index children already receiving HIV care or treatment
services and invited eligible family members for enrollment into the FCCM directly by using
the FCCM invitation letter or through a phone call. The family unit folder was created, the
program enrollment form completed, and all individual chronic care files retrieved for all family
members and put into the family folder. Each family folder was given an FCCM number that
was also documented on the patient booklet. Invitations for index testing were provided by the
HTS counselors on their return.
3. Organization of family folders and scheduling family appointments
Nurses scheduled follow up appointments for all individuals in the family unit enrolled in
FCCM on the same day and completed documentation in the chronic care file and patient
booklet. The expert client completed documentation of the family appointment date into the
appointment register, and the expert client or data clerk refiled the family folder according to
the family unit number in the designated filing cabinet. Appointment reminders were sent to
the family 3 days before their appointment visit.
4. Family follow up visits before arrival at the facility
The expert clients and data clerks retrieved all family folders for families scheduled for a
particular day and the nurse reviewed the individual chronic care files to request or follow up
particular lab tests, results, or other care as needed. Medications were prepared for family
units at two clinics (Horo and Mangweni). However, at Emkhuzweni Health Centre and Pigg’s
Peak Hospital, pending authorization for drug distribution in the hospitals and health centers,
prescriptions were written and dispensed on the day of the visit.
5. Family follow up visits on arrival at the facility
Family units were “fast tracked” to the expert client on arrival, circumventing some of the lines
for receiving care, and documentation was updated in the appointment register.
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APPENDIX 5
FAM-CARE PACKAGE OF SERVICES
ART clinic
Multi-disciplinary team: AIDSFree mentors, facility doctors, nurses, expert clients, social workers,
HTS counselor, phlebotomist, pharmacy personnel, data clerks
Service provided
Clinic
visits

1.

Family-centered assessment of adherence

2.

Family-centered adherence support

3.

Family counseling and assisted disclosure support

4.

Patient education in the context of the family to increase patient adherence, treatment, and
viral load literacy in preparation for long term adherence +/- a change in ART regimen.

5.

Medical history and examination

6.

Screening and treating comorbidities/opportunistic infections

7.

Refill ARVs and prophylactic medications (CTX, IPT, Fluconazole) and adjust ART doses and
schedule (same appointments for all individuals in the family unit enrolled in FAM-CARE)

8.

Laboratory monitoring

9.

Index testing for family members for ART initiation

10. Referrals for other services (social worker support, nutritional support, cervical cancer
screening, family planning, etc.)
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APPENDIX 6
EGPAF EVIDENCE TO ACTION: URGENT UPDATE! OPTIMIZING
PEDIATRIC REGIMENS BRIEF
Available on next page and available for download here: https://www.pedaids.org/resource/
optimizing-pediatric-regimens/.
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APPENDIX 7
A MAP OF ESWATINI FAM-CARE STUDY SITES AND
CATCHMENT AREA
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